Malignant mesothelioma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A malignant neoplasm of the pleura or peritoneum, arising from mesothelial cells. It is associated with exposure to asbestos.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Malignant mesothelioma
- Therapeutic area
- Oncology
- malignant mesothelioma
- malignant mesothelial tumor
- malignant mesothelial tumour
- malignant mesothelioma
- malignant mesothelioma (disease)
- malignant neoplasm of mesothelium
- malignant neoplasm of the mesothelium
- malignant tumor of mesothelium
- malignant tumor of the mesothelium
- malignant tumour of mesothelium
- malignant tumour of the mesothelium
- mesothelioma, malignant
- mesothelioma, somatic
- advanced malignant mesothelioma
- asbestos-related malignant mesothelioma
- diffuse malignant mesothelioma
- malignant mesothelial neoplasm
- MESOM
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0006292
- Parent condition
- MONDO:0004992
Related records
Broader conditions (9)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Mesothelial neoplasm
- Mesothelioma
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (15)
- Diffused pleural mesothelioma
- Localized pleural mesothelioma
- Lymphohistiocytoid mesothelioma
- Malignant biphasic mesothelioma
- Malignant epithelioid mesothelioma
- Malignant pericardial mesothelioma
- Malignant peritoneal mesothelioma
- Malignant pleural mesothelioma
- Mesothelioma of the tunica vaginalis
- Ovarian malignant mesothelioma
- Pleural biphasic mesothelioma
- Pleural epithelioid mesothelioma
- Pleural mesothelioma in situ
- Pleural sarcomatoid mesothelioma
- Sarcomatoid mesothelioma
Trials (327)
- ......SMARTEST Trial......
- 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
- A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
- A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
- A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
- A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
- A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
- A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
- A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
- A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
- A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
- A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
- A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Approved drugs (3)
- Ipilimumab
- Pemetrexed disodium
- Pemetrexed monohydrate
Drugs in development (9)
- Bortezomib Phase 2
- Brentuximab vedotin Phase 2
- Carboplatin Phase 2
- Cisplatin Phase 2
- Nivolumab Phase 2
- Pemetrexed Phase 2
- Ramucirumab Phase 2
- Tremelimumab Phase 3
- VS-5584 Phase 1